The estimated Net Worth of Julie O'neill is at least $6.42 million dollars as of 27 February 2018. Ms. neill owns over 1,625 units of Hookipa Pharma Inc stock worth over $225,915 and over the last 10 years she sold HOOK stock worth over $6,033,976. In addition, she makes $164,582 as Independent Director at Hookipa Pharma Inc.
Sign up
Ms. Neill HOOK stock SEC Form 4 insiders trading
Julie has made over 16 trades of the Hookipa Pharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she sold 1,625 units of HOOK stock worth $194,724 on 27 February 2018.
The largest trade she's ever made was selling 11,665 units of Hookipa Pharma Inc stock on 27 February 2015 worth over $1,183,881. On average, Julie trades about 1,833 units every 43 days since 2015. As of 27 February 2018 she still owns at least 42,787 units of Hookipa Pharma Inc stock.
You can see the complete history of Ms. neill stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Julie O Neill biography
Julie O Neill serves as Independent Director of the Company. Ms. O'Neill previously served as the Executive Vice President, Global Operations of Alexion Pharmaceuticals, Inc., a position she held from January 2015 to September 2018. From February 2014 to January 2015, Ms. O'Neill was Senior Vice President of Global Manufacturing Operations and General Manager of Alexion Pharma International Trading. Prior to joining Alexion, Ms. O'Neill served in various leadership positions at Gilead Sciences, Inc., or Gilead, from 1997 to 2014 including Vice President of Operations and General Manager of Ireland from 2011 to 2014. Prior to Gilead, Ms. O'Neill held leadership positions at Burnil Pharmacies and Helsinn Birex Pharmaceuticals. She was previously Chairperson for the National Standards Authority of Ireland and is a member of the board and chairs the audit committee of the National Institute for Bioprocessing Research & Training. Ms. O'Neill serves as member of the board of directors of DBV Technologies S.A. (Nasdaq: DBVT) and ICON plc. Our Board of Directors believes that Ms. O'Neill's experience in the life sciences industry and her knowledge of corporate development matters qualify her to serve on our Board of Directors.
What is the salary of Julie Neill?
As the Independent Director of Hookipa Pharma Inc, the total compensation of Julie Neill at Hookipa Pharma Inc is $164,582. There are 12 executives at Hookipa Pharma Inc getting paid more, with Joern Aldag having the highest compensation of $6,367,980.
How old is Julie Neill?
Julie Neill is 54, she's been the Independent Director of Hookipa Pharma Inc since 2018. There are 7 older and 10 younger executives at Hookipa Pharma Inc. The oldest executive at Hookipa Pharma Inc is Prof. Rolf M. Zinkernagel M.D., Ph.D., 77, who is the Co-Founder.
What's Julie Neill's mailing address?
Julie's mailing address filed with the SEC is C/O HOOKIPA PHARMA INC., 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY, 10118.
Insiders trading at Hookipa Pharma Inc
Over the last 21 years, insiders at Hookipa Pharma Inc have traded over $12,222,300 worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth $18,573,557 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... et Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of $180,581. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth $5,110.
What does Hookipa Pharma Inc do?
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
What does Hookipa Pharma Inc's logo look like?
Complete history of Ms. neill stock trades at Alexion Pharmaceuticals et Hookipa Pharma Inc
Hookipa Pharma Inc executives and stock owners
Hookipa Pharma Inc executives and other stock owners filed with the SEC include:
-
Joern Aldag,
Chief Executive Officer, Director -
Reinhard Kandera,
Chief Financial Officer, Director -
Igor Matushansky,
Chief Medical Officer and Global Head of Research and Development -
Joern Aldag,
CEO & Director -
Dr. Igor Matushansky M.D., Ph.D.,
Chief Medical Officer and Global Head of R&D -
Dr. Reinhard Kandera,
CFO & Director -
Sander van Deventer,
Independent Director -
Graziano Seghezzi,
Independent Director -
Jan van de Winkel,
Independent Chairman of the Board -
Michael Kelly,
Independent Director -
David Kaufman,
Independent Director -
Christoph Lengauer,
Independent Director -
Julie O Neill,
Independent Director -
Jean-Charles Soria,
Director -
Roman Necina,
Chief Technology Officer -
Klaus Orlinger,
Executive Vice President - Research -
Dr. Klaus Orlinger Ph.D.,
Exec. VP of Research -
Nina Waibel,
Sr. Director of Communications -
Marine Popoff,
Communications & Investor Relations Mang. -
Dr. Roman Necina Ph.D.,
Chief Technology Officer -
Lukas Flatz,
Co-Founder -
Andreas Bergthaler,
Co-Founder -
Prof. Rolf M. Zinkernagel M.D., Ph.D.,
Co-Founder -
Jerry D Jones,
Director -
Bros. Advisors Lp Baker Bro...,
-
Capital Fund Ii Cooperatief...,
10% owner -
David Pinschewer,
Chief Scientific Officer -
Group, Llc Green Jeremy Red...,
-
Capital Vi Fcpr Sofinnova P...,
-
Anders Lilja,
Sr. VP, Technical Development -
Timothy P. Reilly,
-
Andrew R Goeler,
Director -
Mark D Moreland,
Chief Financial Officer -
John D Jr Rogers,
Director -
Martin J Iv Wall,
Vice President, Sales -
David R Lord,
Director -
V Sebastian Pastore,
VP, Brewing Operations & Tech -
Marc J Cramer,
Director -
Terry E Michaelson,
Co-Chief Executive Officer -
Kurt R Widmer,
Director -
Danielle A Katcher,
Vice President, Marketing -
Kevin R Kelly,
Director -
Timothy P Boyle,
Director -
David J Mickelson,
President & COO -
Companies, Inc.Busch Invest...,
-
Frank H Clement,
Director -
Ann G Widmer,
10% owner -
Anthony J Short,
Director -
Kurt R Widmer Ann G Widmer,
-
Paul S Shipman,
President & CEO -
Michael Loughran,
Director -
Katia Schlienger,
Chief Medical Officer -
Jorn Aldag,
Chief Executive Officer -
Christine D. Baker,
Chief Operating Officer -
Mark Winderlich,
Chief Development Officer -
Mary Theresa Coelho,
EVP and CFO -
Malte Peters,
Chief Executive Officer -
Sean A Cassidy,